Study Findings Underscore Benefits Of SARS-CoV-2 Vaccination In People With MM

The American Journal of Managed Care (1/9, Munz) reports research found that “patients with multiple myeloma (MM) produce fewer antibodies while going through lenalidomide (Lena; Revlimid) maintenance therapy,” but “after receiving a SARS-CoV-2 vaccination...their T-cell response resembles that of healthy populations.” The findings “underscore the benefits of SARS-CoV-2 vaccination in the MM population.” The findings were published in Frontiers in Immunology.